Last update Aug. 20, 2022


Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is a dihydropyridine calcium channel blocker, peripheral and coronary vasodilator, indicated for the treatment of angina pectoris and hypertension. Oral administration once or twice daily.

It is excreted into breast milk in non-significant amount (Malfará 2019, Taddio 1996, Manninen 1991, Ehrenkranz 1989, Penny 1989) with no problems among breastfed infants whose mothers were treated with this medication. (Wu 2012, O'Sullivan 2011, Page 2006, Anderson 2004, Garrison 2002, Lawlor 1997, Penny 1989)

No alteration on breast milk composition or production has been seen. (Magee 2005)

Shown to be effective at a dose of 10 - 20 mg three times-a-day for pain relief related to Raynaud phenomenon of the nipple. (Di Como 2020, Barrett 2013, Anderson 2004, Garrison 2002)

Possible side effects (headache, hypotension) in the mother should be monitored. Gynecomastia may occur with the use of nifedipine and other calcium channel blockers. (Deepinder 2012, Tanner 1988)

Several medical societies, experts and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding (Hale, LactMed, Malachias 2016, Briggs 2015, Schaefer 2015, Serrano 2015, Rowe 2013, Dennis 2012, Chen 2010, Ghanem 2008). American Academy of Pediatrics 2001: Maternal Medication Usually Compatible With Breastfeeding. (AAP 2001). Eleventh WHO Model List of Essential Drugs 2002: Compatible with breastfeeding. (WHO 2002)


We do not have alternatives for Nifedipine since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Nifedipine in other languages or writings:


Variable Value Unit
Oral Bioavail. 45 - 68 %
Molecular weight 346 daltons
Protein Binding 92 - 98 %
VD 0.25 - 0.69 l/Kg
pKa 16.94 -
Tmax 0.75 - 4. 2 hours
2 - 5 hours
M/P ratio 1 -
Theoretical Dose 0.008 mg/Kg/d
Relative Dose 1.6 %
Ped.Relat.Dose 0.01 - 0.1 %


  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from Consulted on March 17, 2022 Full text (link to original source)
  2. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: 2006 - Consulted on March 15, 2022 Full text (link to original source)
  3. Di Como J, Tan S, Weaver M, Edmonson D, Gass JS. Nipple pain: Raynaud's beyond fingers and toes. Breast J. 2020 Oct;26(10):2045-2047. Abstract
  4. Malfará BN, Benzi JRL, de Oliveira Filgueira GC, Zanelli CF, Duarte G, de Carvalho Cavalli R, de Moraes NV. ABCG2 c.421C>A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women. Reprod Toxicol. 2019 Apr;85:1-5. Abstract
  5. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source) Full text (in our servers)
  6. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  7. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  8. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, Third Edition. 2015
  9. Barrett ME, Heller MM, Stone HF, Murase JE. Raynaud phenomenon of the nipple in breastfeeding mothers: an underdiagnosed cause of nipple pain. JAMA Dermatol. 2013 Abstract
  10. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  11. Wu M, Chason R, Wong M. Raynaud's phenomenon of the nipple. Obstet Gynecol. 2012 Abstract
  12. Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012 Sep;11(5):779-95. Abstract
  13. Dennis AT. Management of pre-eclampsia: issues for anaesthetists. Anaesthesia. 2012 Sep;67(9):1009-20. Abstract Full text (link to original source) Full text (in our servers)
  14. O'Sullivan S, Keith MP. Raynaud phenomenon of the nipple: a rare finding in rheumatology clinic. J Clin Rheumatol. 2011 Abstract
  15. Chen LH, Zeind C, Mackell S, LaPointe T, Mutsch M, Wilson ME. Breastfeeding travelers: precautions and recommendations. J Travel Med. 2010 Jan-Feb;17(1):32-47. Abstract Full text (link to original source) Full text (in our servers)
  16. Ghanem FA, Movahed A. Use of antihypertensive drugs during pregnancy and lactation. Cardiovasc Ther. 2008 Abstract Full text (link to original source) Full text (in our servers)
  17. Page SM, McKenna DS. Vasospasm of the nipple presenting as painful lactation. Obstet Gynecol. 2006 Abstract
  18. Magee L, Sadeghi S. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2005 Abstract
  19. Anderson JE, Held N, Wright K. Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding. Pediatrics. 2004 Abstract Full text (link to original source) Full text (in our servers)
  20. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Full text (link to original source) Full text (in our servers)
  21. Garrison CP. Nipple vasospasms, Raynaud's syndrome, and nifedipine. J Hum Lact. 2002 Abstract
  22. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  23. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Abstract
  24. Lawlor-Smith LS, Lawlor-Smith CL. Raynaud's phenomenon of the nipple: a preventable cause of breastfeeding failure? Med J Aust. 1997 Abstract
  25. Taddio A, Oskamp M, Ito S, Bryan H, Farine D, Rvan D, Koren G. Is nifedipine use during labour and breast-feeding safe for the neonate? Clin Investig Med. 1996;19:S11 Abstract Full text (link to original source)
  26. Manninen AK, Juhakoski A. Nifedipine concentrations in maternal and umbilical serum, amniotic fluid, breast milk and urine of mothers and offspring. Int J Clin Pharmacol Res. 1991 Abstract
  27. Penny WJ, Lewis MJ. Nifedipine is excreted in human milk. Eur J Clin Pharmacol. 1989 Abstract
  28. Ehrenkranz RA, Ackerman BA, Hulse JD. Nifedipine transfer into human milk. J Pediatr. 1989 Abstract
  29. Tanner LA, Bosco LA. Gynecomastia associated with calcium channel blocker therapy. Arch Intern Med. 1988 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM